Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ - Friday, June 28, 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:
| 1. | Name of applicant:
| | HUTCHMED (China) Limited
| |
| 2. | Name of scheme:
| | Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")
| |
| | | |||
| 3. | Period of return:
| | From December 29, 2023 to June 28, 2024
| |
| 4. | Balance under scheme from previous return:
| | 2015 HUTCHMED Share Option Scheme: 46,847,218 ordinary shares of US$0.1 each
| |
| | ||||
| 5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
| | 2015 HUTCHMED Share Option Scheme: Nil
| |
| | | |||
| 6. | Number of securities issued/allotted under scheme during period:
| | 2015 HUTCHMED Share Option Scheme: 103,450
| |
| | | |||
| 7. | Balance under scheme not yet issued/allotted at end of the period:
| | 2015 HUTCHMED Share Option Scheme: 46,743,768 ordinary shares of US$0.1 each
| |
| | | |||
| 8. | Number and class of securities originally listed and the date of admission:
| | 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) | |
| | | |||
| | | |||
| | | |||
| | | | | |
| 9. | Total number of securities in issue at the end of the period:
| | 871,359,720 ordinary shares of US$0.1 each | |
| Name of contact:
| | Weiguo Su | ||
| Address of contact:
| | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
| ||
| Telephone number of contact: | | +852 2121 8200 | ||
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| | |
| Media Enquiries | |
| Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com |
| Zhou Yi, Brunswick | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| | |
| Nominated Advisor | |
| Atholl Tweedie / Freddy Crossley / | +44 (20) 7886 2500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.